Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

I do NOT see the need to partner for Covid. But under the scenario you propose, one of my questions would be, “Who makes the decision as to how to allocate revenue for a combo therapy?” I could see a situation where Gilead would try to give Remdesivir the lion’s share of the revenue since they would then not have to give as large of a revenue split to IPIX. If we were going to partner, I think I would prefer we do it with someone who does not have a “competing” product.

Attila said, [

i]If B's 3-in-1 only impacts Gilead's Remdesivir, then Gilead should be pursing IP if trials are deemed successful.